A Primary Care Perspective on Prescribing for Women

Chapter

Abstract

A recent paper indicates that in older patients receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers, co-trimoxazole is associated with an increased risk of sudden death. This is probably related to trimpethoprim-induced sudden hyperkalemia. Other drugs such as nitrofurantoin should be chosen first line where a woman is taking an ACE or an ARB, or potassium should be monitored, Fralick et al. (BMJ 349:g6196, 2014).

Keywords

Primary Care Edinburgh Postnatal Depression Scale Primary Care Clinician Prescribe Medicine Primary Care Doctor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alexander GC, Sayla MA, Holmes HM, Sachs GA (2006) Prioritizing and stopping prescription medicines. CMAJ 174:1083–1084PubMedCentralPubMedCrossRefGoogle Scholar
  2. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, Mcphillips H, Roblin D, Smith DH, Yood MU, Platt R, Gurwitz JH (2006) Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 15:546–554PubMedCrossRefGoogle Scholar
  3. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:449–456PubMedCentralPubMedCrossRefGoogle Scholar
  4. Ashton H (1991) Psychotropic-drug prescribing for women. Br J Psychiatry 158(Suppl 10):30–35Google Scholar
  5. Baker GR, Norton PG, Flintoft V, Blais R, Brown A, Cox J, Etchells E, Ghali WA, Hébert P, Majumdar SR, O’beirne M, Palacios-Derflingher L, Reid RJ, Sheps S, Tamblyn R (2004) The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 170:1678–1686PubMedCentralPubMedCrossRefGoogle Scholar
  6. Bednar MM, Harrigan EP, Ruskin JN (2002) Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 89:1316–1319PubMedCrossRefGoogle Scholar
  7. Bell RA, Kravitz RL, Wilkes MS (2000) Direct-to-consumer prescription drug advertising, 1989–1998. A content analysis of conditions, targets, inducements, and appeals. J Fam Prac 49:329–335Google Scholar
  8. Benton RE, Sale M, Flockhart DA, Woosley RL (2000) Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 67:413–418PubMedCrossRefGoogle Scholar
  9. Blenkinsopp A, Wilkie P, Wang M, Routledge PA (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 63:148–156PubMedCentralPubMedCrossRefGoogle Scholar
  10. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294:716–724PubMedCrossRefGoogle Scholar
  11. BPAC (2010) A practical guide to stopping medicines in older people. BPJ 27:10–23Google Scholar
  12. BPAC NZ (2011) Antibiotics – choices for common infections [Internet]. New Zealand: BPACNZ. Cited 18 Jan 2013. Available: http://www.bpac.org.nz/resources/handbook/antibiotics/antibiotics_guide.asp
  13. Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM (2004) Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. J Health Commun 9:491–497PubMedCrossRefGoogle Scholar
  14. Buchanan FF, Myles PS, Cicuttini F (2011) Effect of patient sex on general anaesthesia and recovery. Br J Anaesth 106(6):832–839PubMedCrossRefGoogle Scholar
  15. Buck MD, Atreja A, Brunker CP, Jain A, Suh TT, Palmer RM, Dorr DA, Harris CM, Wilcox AB (2009) Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother 7:84–92PubMedCrossRefGoogle Scholar
  16. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM (1999) Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 47:850–853PubMedGoogle Scholar
  17. CDC (1997) Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations. MMWR 46:1061–1066Google Scholar
  18. CDC CFDCAP (2011) Preventing and managing chronic disease to improve the health of women and infants. Division of Reproductive HealthGoogle Scholar
  19. Chilet-Rosell E, Ruiz-Cantero T, Fernández Sáez J, Álvarez-Dardet C (2013) Inequality in analgesic prescription in Spain a gender development issue. Gac Sanit 27:135–142PubMedCrossRefGoogle Scholar
  20. Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne JAC, Taylor RS (2013) Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ 346:f457PubMedCentralPubMedCrossRefGoogle Scholar
  21. CIHI (2011) Seniors and the health care system: what is the impact of multiple chronic conditions? https://secure.cihi.ca/free_products/air-chronic_disease_aib_en.pdf. Canadian Institute for Health Information
  22. Cochrane AL, Holland WW (1971) Validation of screening procedures. Br Med Bull 25:3–8Google Scholar
  23. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499–507PubMedCrossRefGoogle Scholar
  24. Coogan PF (2013) Calcium-channel blockers and breast cancer: a hypothesis revived. JAMA Intern Med 173:1637–1638PubMedCrossRefGoogle Scholar
  25. Cotton P (1993) FDa lifts ban on women in early drug tests, will require companies to look for gender differences. JAMA 269:2067PubMedCrossRefGoogle Scholar
  26. Cross C (2013) Introducing deprescribing into culture of medication. CMAJ 185(13):E606PubMedCentralPubMedCrossRefGoogle Scholar
  27. Currie J (2003) Manufacturing addiction: the over-prescription of benzodiazepines and sleeping pills to women in Canada. British Columbia Centre of Excellence for Women’s Health [Policy Series]. http://bccewh.bc.ca/publicationsresources/publications/page/6/
  28. Daw JR, Hanley GE, Greyson DL, Morgan SG (2011) Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 20:895–902PubMedCentralPubMedGoogle Scholar
  29. Domecq C, Naranjo CA, Ruiz I, Busto U (1980) Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 18:362–366PubMedGoogle Scholar
  30. Drolet B, Simard C, Poirier P (2007) Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs. Am J Cardiovasc Drugs 7:273–288PubMedCrossRefGoogle Scholar
  31. Ebert SN, Liu XK, Woosley RL (1998) Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 7:547–557PubMedCrossRefGoogle Scholar
  32. Eisenberg DL, Stika C, Desai A, Baker D, Yost KJ (2010) Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians’ knowledge, attitudes and barriers. J Gen Intern Med 25:291–297PubMedCentralPubMedCrossRefGoogle Scholar
  33. Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ (2000) Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol 49:158–167PubMedCentralPubMedCrossRefGoogle Scholar
  34. Field TS, Gilman BH, Subramanian S, Fuller JC, Bates DW, Gurwitz JH (2005) The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 43:1171–1176PubMedCrossRefGoogle Scholar
  35. Figueras A, Capella D, Castel JM, Laorte JR (1994) Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations. Eur J Clin Pharmacol 47:297–303PubMedCrossRefGoogle Scholar
  36. Foxman B (2003) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49:53–70PubMedCrossRefGoogle Scholar
  37. Fralick M, Juulink D et al (2014) Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 349:g6196PubMedCentralPubMedCrossRefGoogle Scholar
  38. Gallagher P, O’Mahony D (2008) STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing 37:673–679PubMedCrossRefGoogle Scholar
  39. Garfinkel D, Mangin D (2010) Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 170:1648–1654PubMedCrossRefGoogle Scholar
  40. Garfinkel D, Zur-Gil S, Ben-Israel J (2007) The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 9:430–434PubMedGoogle Scholar
  41. Geller SE, Koch A, Pellettieri B, Carnes M (2011) Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Womens Health (Larchmt) 20:315–320CrossRefGoogle Scholar
  42. Gilbody SM, House AO, Sheldon TA (2005) Screening and case finding for depression. Cochrane Database Syst Rev (4):CD002792Google Scholar
  43. Golomb BA, Mcgraw JJ, Evans MA, Dimsdale JE (2007) Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 30:669–675PubMedCrossRefGoogle Scholar
  44. Gu Q, Dillon C, Burt VL (2010) Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008, NCHS data brief. National Center for Health Statistics, Hyattsville (pp. 8)Google Scholar
  45. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, Cohen HJ, Feussner JR (1992) A method for assessing drug therapy appropriateness. J Clin Epidemiol 45:1045–1051PubMedCrossRefGoogle Scholar
  46. Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222–239PubMedCrossRefGoogle Scholar
  47. Hausken AM, Skurtveit S, Rosvold EO, Bramness JG, Furu K (2007) Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway. Scand J Public Health 35:356–364PubMedCrossRefGoogle Scholar
  48. Heinrich J (2001) Drug safety: most drugs withdrawn in recent years had greater health risks for women, GAO 01286R. United States General Accounting Office, Washington, DCGoogle Scholar
  49. Herxheimer A, Crombag R, Alves T (2010) Direct patient reporting of adverse drug reactions a fifteen-country survey & literature review. Health Action International (HAI) EuropeGoogle Scholar
  50. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, Harris TB, Hanlon JT, Rubin SM, Shorr RI, Bauer DC, Abernethy DR (2007) A drug burden index to define the functional burden of medications in older people. Arch Intern Med 167:781–787PubMedCrossRefGoogle Scholar
  51. Holmes HM, Hayley DC, Alexander GC, Sachs GA (2006) Reconsidering medication appropriateness for patients late in life. Arch Intern Med 166:605–609PubMedCrossRefGoogle Scholar
  52. Iyer S, Naganathan V, Mclachlan AJ, Le Conteur DG (2008) Medication withdrawal trials in people aged 65 years and older. Drugs Aging 25:1021–1031PubMedCrossRefGoogle Scholar
  53. Kando JC, Yonkers KA, Cole JO (1995) Gender as a risk factor for adverse events to medications. Drugs 50:1–6PubMedCrossRefGoogle Scholar
  54. Katerndahl D, Wood R, Jaen CR (2011) Family medicine outpatient encounters are more complex than those of cardiology and psychiatry. J Am Board Fam Med 24(1):6–15PubMedCrossRefGoogle Scholar
  55. Kendrick T, Hegarty K, Glaziou P (2008) Interpreting research findings to guide treatment in practice. BMJ 337. doi:10.1136/bmj.a1499Google Scholar
  56. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. J Affect Disord 117(Suppl 1):S1–S2PubMedCrossRefGoogle Scholar
  57. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095–3105PubMedCrossRefGoogle Scholar
  58. Klungel OH, DE Boer A, Paes AH, Seidell JC, Bakker A (1997) Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens 15:591–600PubMedCrossRefGoogle Scholar
  59. Klungel OH, De Boer A, Paes AH, Seidell JC, Bakker A (1998) Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens 16:1545–1553PubMedCrossRefGoogle Scholar
  60. Kost K, Singh S, Vaughan B, Trussell J, Bankole A (2008) Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 77:10–21PubMedCentralPubMedCrossRefGoogle Scholar
  61. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P (2005) Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 293:1995–2002PubMedCentralPubMedCrossRefGoogle Scholar
  62. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–1205PubMedCrossRefGoogle Scholar
  63. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590–2597PubMedCrossRefGoogle Scholar
  64. Malmusi D, Artazcoz L, Benach J, Borrell C (2012) Perception or real illness? How chronic conditions contribute to gender inequalities in self-rated health. Eur J Public Health 22:781–786PubMedCrossRefGoogle Scholar
  65. Mangin D, Kerse N (2010) When is enough, enough? Stopping medicines in older people. Best Practice J 27:6–9Google Scholar
  66. Mangin D, Heath I, Jamoulle M (2012) Beyond diagnosis: responding to the comorbidity challenge. BMJ 44:e3526 (in press)CrossRefGoogle Scholar
  67. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD (1998) Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 46:505–511PubMedCentralPubMedCrossRefGoogle Scholar
  68. Mccarthy L, Dolovich L, Haq M, Thabane L, Kaczorowski J (2007) Frequency of risk factors that potentially increase harm from medications in older adults receiving primary care. Can J Clin Pharmacol 14:e283–e290PubMedGoogle Scholar
  69. Mcgarvey WC, Singh D, Trevino SG (1996) Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 17:496–498PubMedCrossRefGoogle Scholar
  70. Medco Health Solutions & Society for Women's Health Research (2012) More is sometimes less: women are prescribed a greater number of medications than men but take less of the drugs they need [Press release]. http://phx.corporate-ir.net/phoenix.zhtml?c=69641&p=irol-MedcoPressArticle&ID=1673845&highlight=%29
  71. Mintzes B (2004) Drug regulatory failure in Canada: the case of Diane-35. Women and Health Protection. http://www.whp-apsf.ca/en/documents/diane35.html
  72. Mintzes B (2010) “Ask your doctor”: women and direct-to-consumer advertising. In: Ford AR, Saibil D (eds) The push to prescribe: women and Canadian Drug Policy. Women’s Press, TorontoGoogle Scholar
  73. Mintzes B, Mangin D (2009) Opinion: direct-to-consumer advertising of prescription medicines: a counter argument. Future Med Chem 1:1555–1560PubMedCrossRefGoogle Scholar
  74. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T (2009) Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339:b4361CrossRefGoogle Scholar
  75. Movin T, Gad A, Guntner P, Foldhazy Z, Rolf C (1997) Pathology of the Achilles tendon in association with ciprofloxacin treatment. Foot Ankle Int 18:297–299PubMedCrossRefGoogle Scholar
  76. Munce SE, Robertson EK, Sansom SN, Stewart DE (2004) Who is portrayed in psychotropic drug advertisements? J Nerv Ment Dis 192:284–288PubMedCrossRefGoogle Scholar
  77. NCCMH (2010) Depression: the treatment and management of depression in adults (Update). The British Psychological Society and the Royal College of Psychiatrists, Leicester/London. [Full guideline]Google Scholar
  78. Nelson MR, Reid CM, Krum H, Muir T, Ryan P, Mcneil JJ (2002) Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort. BMJ 325:815–817PubMedCentralPubMedCrossRefGoogle Scholar
  79. Nicholas R, Lee N, Roche A (2011) Pharmaceutical drug misuse in Australia: complex problems, balanced responses. National Centre for Education and Training on Addiction (NCETA), AdelaideGoogle Scholar
  80. Oates M (2003) Postnatal depression and screening: too broad a sweep? Br J Gen Pract 53:596–597PubMedCentralPubMedGoogle Scholar
  81. Ochs HR, Greenblatt DJ, Divoll M, Abernethy DR, Feyerabend H, Dengler HJ (1981) Diazepam kinetics in relation to age and sex. Pharmacology 23:24–30PubMedCrossRefGoogle Scholar
  82. OECD (2013) Health at a glance 2013: OECD indicators. OECD Publishing, Paris. http://dx.doi.org/10.1787/health_glance-2013-en
  83. Ostini R, Jackson C, Hegney D, Tett SE (2011) How is medication prescribing ceased? A systematic review. Med Care 49:24–36PubMedCrossRefGoogle Scholar
  84. PHARMAC – Pharmaceutical Management Agency. PHARMAC data relating to antidepressant prescribing and costs – 13 year trends and regional variation. PHARMAC, WellingtonGoogle Scholar
  85. Pouyanne P, Haramburu F, Imbs JL, Bégaud B (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 320:1036PubMedCentralPubMedCrossRefGoogle Scholar
  86. Pratt L, Brody D, Gu Q (2011) Antidepressant use in persons aged 12 and over: United States, 2005–2008 NCHS Data BriefGoogle Scholar
  87. Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2:349–351PubMedCrossRefGoogle Scholar
  88. Richards D, Toop L, Chambers ST, Sutherland M, Harris B, Ikram R, Jones M, Mcgeoch G, Peddie B (2002) Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J 115:12–14PubMedGoogle Scholar
  89. Richards D, Toop L, Chambers S, Fletcher L (2005) Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: double blind randomised controlled trial. BMJ 331:143–147PubMedCentralPubMedCrossRefGoogle Scholar
  90. Roberts H, Redberg R (2013) Gender disparity in statin response: are statins less effective in women? Clin Lipidol 8:161–163CrossRefGoogle Scholar
  91. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn't. BMJ 312:71–72PubMedCentralPubMedCrossRefGoogle Scholar
  92. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA (2011) Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 61:e12–e21PubMedCentralPubMedCrossRefGoogle Scholar
  93. Schwarz EB, Maselli J, Norton M, Gonzales R (2005) Prescription of teratogenic medications in United States ambulatory practices. Am J Med 118:1240–1249PubMedCrossRefGoogle Scholar
  94. Scott IA, Gray LC, Martin JH, Mitchell CA (2012) Minimizing inappropriate medications in older populations: a 10-step conceptual framework. Am J Med 125:529–537.e4PubMedCrossRefGoogle Scholar
  95. Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH, Grossman E (2002) Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens 16:6331–6635CrossRefGoogle Scholar
  96. Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, Aikat S (2013) Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest 144:1311–1322PubMedCrossRefGoogle Scholar
  97. Simoni-Wastila L (2000) The use of abusable prescription drugs: the role of gender. J Womens Health Gend Based Med 9:289–297PubMedCrossRefGoogle Scholar
  98. Spigset O (1999) Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20:277–287PubMedCrossRefGoogle Scholar
  99. Steinkellner A, Chen W, Denison SE (2010) Adherence to oral contraception in women on category X medications. Am J Med 123:929–934.e1PubMedCrossRefGoogle Scholar
  100. Steinman MA, Lund BC, Miao Y, Boscardin WJ, Kaboli PJ (2011) Geriatric conditions, medication use, and risk of adverse drug events in a predominantly male, older veteran population. J Am Geriatr Soc 59:615–621PubMedCentralPubMedCrossRefGoogle Scholar
  101. Therapeutics Initiative: Evidence Based Drug Therapy (2005) Drugs for overactive bladder symptoms. Department of Pharmacology & Therapeutics, University of British Columbia, VancouverGoogle Scholar
  102. Thorpe KE, Howard DH (2006) The rise in spending among Medicare beneficiaries: the role of chronic disease prevalence and changes in treatment intensity. Health Aff (Millwood) 25:w378–w388CrossRefGoogle Scholar
  103. Toop L, Richards D (2003) New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit? N Z Med J 116:6Google Scholar
  104. Toop L, Richards D, Dowell T, Fraser T, Tilyard M, Arroll B (2003a) DTCA of prescription medicines in New Zealand: for health or for profit. Report update June 2003. Christchurch School of Medicine, ChristchurchGoogle Scholar
  105. Toop L, Richards D, Dowell T, Tilyard M, Fraser T, Arroll B (2003b) Direct-to-consumer advertising of prescription drugs in New Zealand: For health or for profit? Report to the minister of health supporting the case for the ban of DTCA. University of Otago, DunedinGoogle Scholar
  106. Tran C, Knowles SR, Liu BA, Shear NH (1998) Gender differences in adverse drug reactions. J Clin Pharmacol 38:1003–1009PubMedCrossRefGoogle Scholar
  107. U. S. Food and Drug Administration (FDA) (2013) http://www.fda.gov/downloads/Drugs/DrugSafety/UCM335007.pdf
  108. Van Der Klauw MM, Wilson JH, Stricker BH (1998) Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974–1994). Am J Hematol 57:206–211PubMedCrossRefGoogle Scholar
  109. Van Der Sijs H, Kowlesar R, Klootwijk APJ, Nelwan SP, Vulto AG, Van Gelder T (2009) Clinically relevant QTc prolongation due to overridden drug–drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol 67:347–354PubMedCentralPubMedCrossRefGoogle Scholar
  110. Verbrugge LM, Steiner RP (1985) Prescribing drugs to men and women. Health Psychol 4:79–98PubMedCrossRefGoogle Scholar
  111. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S (2008) Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65:573–579PubMedCentralPubMedCrossRefGoogle Scholar
  112. Wolfe S (2012) The seven-year rule for safer prescribing. Aust Prescr 35:138–139Google Scholar
  113. Wong SLF, Wester F, Mol S, Römkens R, Lagro-Janssen T (2007) Utilisation of health care by women who have suffered abuse: a descriptive study on medical records in family practice. Br J Gen Pract 57:396–400PubMedCentralGoogle Scholar
  114. Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89:1363–1372PubMedCentralPubMedCrossRefGoogle Scholar
  115. Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, Brunetto WL, Lin H, Burkman RT, Zelop CM, Lockwood CJ (2011) Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 22:848–854PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Family MedicineMcMaster UniversityHamiltonCanada
  2. 2.University of OtagoChristchurch, DunedinNew Zealand

Personalised recommendations